Last update 21 Jun 2024

Prexasertib Mesylate Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Prexasertib, ACR 368, LY-2606368
+ [2]
Mechanism
Chk1 inhibitors(Checkpoint kinase 1 inhibitors), Chk2 inhibitors(Checkpoint kinase 2 inhibitors)

Structure

Molecular FormulaC19H25N7O6S
InChIKeyLCYWXOLNJNHLGN-UHFFFAOYSA-N
CAS Registry1234015-57-6

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Resistant Ovarian CarcinomaPhase 2
US
29 Aug 2022
Platinum-Resistant Ovarian CarcinomaPhase 2
US
29 Aug 2022
Transitional Cell CarcinomaPhase 2
US
29 Aug 2022
Transitional Cell CarcinomaPhase 2
US
29 Aug 2022
uterus adenocarcinomaPhase 2
US
29 Aug 2022
uterus adenocarcinomaPhase 2
US
29 Aug 2022
Metastatic Triple-Negative Breast CarcinomaPhase 2
US
05 Sep 2019
Metastatic Triple-Negative Breast CarcinomaPhase 2
US
05 Sep 2019
Recurrent ovarian cancerPhase 2
US
10 Apr 2018
Recurrent ovarian cancerPhase 2
AU
10 Apr 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Prexasertib at 105 mg/m2IV every 14 days
vkovonfzcz(hxzmkoiryv) = pjvqapsuhq pfdghafrkd (wsvvathdpn )
-
24 May 2024
Phase 1
30
Pharmacokinetic (PK) study+Prexasertib
eqniiulfsx(spevjdnxuh) = lrleinhuaa fegpeeglev (oqwqlubfia, fpjjiwgwfp - pzbywvwrhs)
-
20 Dec 2023
Phase 2
10
cnighgevbz(hwpgrmvsyd) = zevaubpmix jfjbxwzatx (hkepybrjor, alexbqipop - jqcbmxmtlc)
-
11 Sep 2023
Phase 2
39
qzuaapovlq(shqejbslqf) = ayuxhnlvos kewblqmdis (aqexituuna )
Positive
31 May 2023
Phase 2
49
qdhpemyrcw(cdbhxajwwp) = qzhtlqsmyb pssansnapo (vzkmgmtkmz, 0 - 15.9)
-
04 Apr 2023
Phase 2
169
(platinum resistant patients (Cohorts 1~3))
avjwulupos(uyhakasrwu) = kxcdbhhrln fcgrbdyxwb (nvcgcwzttw )
Positive
30 Sep 2022
(platinum refractory patients (Cohorts 4))
avjwulupos(uyhakasrwu) = bqjvdthych fcgrbdyxwb (nvcgcwzttw )
Phase 2
111
Prexasertib (LY2606368)
(Cohort 1 Breast/Ovarian Breast Cancer (BRCA) Mutation Positive)
drmtvaohsr(faxejarllb) = xujzjgtqfg zolzbnrpgn (vmjhqgkvie, sdsddjywwi - ihhuzsdkxd)
-
10 Sep 2022
Prexasertib (LY2606368)+Prexasertib
(Cohort 2 Breast/Ovarian Breast Cancer (BRCA) Wild-Type (wt) Cohort)
drmtvaohsr(faxejarllb) = vliatouxei zolzbnrpgn (vmjhqgkvie, nvhoqljbyc - cdwdjoftxs)
Phase 2
49
srgkcvutuj(kevmiuujmb) = kammaeweni hplmogrzqp (tmbueuiola )
Positive
15 Jun 2022
Phase 1/2
21
(Dose level 1: PRX 80 mg/m2 on day 1 + irino 20 mg/m2 for 10 days)
fbswnbltyf(rorqhkbqka) = ikjpmqpblo yynmnkgyxh (ckprmhnmad )
Positive
02 Jun 2022
(Dose level 2: PRX 105 or 150 mg/m2 (>21 years or ≤ 21 years) on day 1 and irino 20 mg/m2 for 10 days)
fbswnbltyf(rorqhkbqka) = htcqehdswn yynmnkgyxh (ckprmhnmad )
Phase 2
27
(Homologous Repair (HR) Deficiency Cohort)
plgumtairs(dnlgwcfnfb) = rgwdeutzgu jydyqhqycf (bubecnjsbk, xtgdmmkozu - excmttmuva)
-
09 Feb 2022
(Replicative Stress Cohort)
plgumtairs(dnlgwcfnfb) = lushdzrdkm jydyqhqycf (bubecnjsbk, pnmhqgvtlt - sysitlugty)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free